Cutler Group LP Zentalis Pharmaceuticals, Inc. Call Options Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Jul 18, 2023	BUY	$17.41 - $30.05 $19,151 - $33,055	1,100 New	1,100 $4,000
Q2 2022 Aug 04, 2022	SELL	$17.91 - $52.25 $73,431 - $214,225	-4,100 Closed	0 $0
Q1 2022 Apr 14, 2022	BUY	$41.58 - $80.89 $170,478 - $331,649	4,100 New	4,100 $2,000
Q4 2021 Jan 18, 2022	SELL	$66.92 - $84.79 $1.16 Million - $1.47 Million	-17,300 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$46.83 - $73.5 $683,718 - $1.07 Million	14,600 Added 540.74%	17,300 $2,000
Q2 2021 Jul 19, 2021	BUY	$37.41 - $62.25 $101,006 - $168,075	2,700 New	2,700 $7,000

140

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $94.6M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.